Condensed Statements of Stockholders’ Equity (Unaudited) - USD ($) $ in Thousands	Total		Common Stock	Additional Paid-In Capital	Accumulated Other Comprehensive Loss	Accumulated Deficit
Beginning balance (in shares) at Dec. 31, 2020			35,552,795
Beginning balance at Dec. 31, 2020	$ 283,061		$ 3	$ 400,918	$ (32)	$ (117,828)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Vesting of restricted stock awards (in shares)			30,277
Vesting of restricted stock awards	2			2
Option exercises (in shares)			165,264
Option exercises	1,370			1,370
Stock-based compensation expense	2,578			2,578
Net unrealized loss on short-term investments	14				14
Net loss	(22,856)					(22,856)
Ending balance (in shares) at Mar. 31, 2021			35,748,336
Ending balance at Mar. 31, 2021	264,169		$ 3	404,868	(18)	(140,684)
Beginning balance (in shares) at Dec. 31, 2020			35,552,795
Beginning balance at Dec. 31, 2020	283,061		$ 3	400,918	(32)	(117,828)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net unrealized loss on short-term investments	2
Net loss	(45,687)
Ending balance (in shares) at Jun. 30, 2021			35,853,916
Ending balance at Jun. 30, 2021	243,980		$ 3	407,522	(30)	(163,515)
Beginning balance (in shares) at Mar. 31, 2021			35,748,336
Beginning balance at Mar. 31, 2021	264,169		$ 3	404,868	(18)	(140,684)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Vesting of restricted stock awards (in shares)			30,136
Vesting of restricted stock awards	2			2
Option exercises (in shares)			75,444
Option exercises	372			372
Stock-based compensation expense	2,280			2,280
Net unrealized loss on short-term investments	(12)				(12)
Net loss	(22,831)					(22,831)
Ending balance (in shares) at Jun. 30, 2021			35,853,916
Ending balance at Jun. 30, 2021	$ 243,980		$ 3	407,522	(30)	(163,515)
Beginning balance (in shares) at Dec. 31, 2021	36,083,301		36,083,301
Beginning balance at Dec. 31, 2021	$ 199,059	[1]	$ 3	414,348	(201)	(215,091)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Vesting of restricted stock awards (in shares)			15,606
Vesting of restricted stock awards	1			1
Option exercises (in shares)			63,552
Option exercises	51			51
Stock-based compensation expense	3,531			3,531
Net unrealized loss on short-term investments	(749)				(749)
Net loss	(28,100)					(28,100)
Ending balance (in shares) at Mar. 31, 2022			36,162,459
Ending balance at Mar. 31, 2022	$ 173,793		$ 3	417,931	(950)	(243,191)
Beginning balance (in shares) at Dec. 31, 2021	36,083,301		36,083,301
Beginning balance at Dec. 31, 2021	$ 199,059	[1]	$ 3	414,348	(201)	(215,091)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net unrealized loss on short-term investments	(1,058)
Net loss	$ (57,646)
Ending balance (in shares) at Jun. 30, 2022	36,182,297		36,182,297
Ending balance at Jun. 30, 2022	$ 147,788		$ 3	421,781	(1,259)	(272,737)
Beginning balance (in shares) at Mar. 31, 2022			36,162,459
Beginning balance at Mar. 31, 2022	173,793		$ 3	417,931	(950)	(243,191)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Vesting of restricted stock awards (in shares)			6,235
Vesting of restricted stock awards	1			1
Option exercises (in shares)			13,603
Option exercises	446			446
Stock-based compensation expense	3,403			3,403
Net unrealized loss on short-term investments	(309)				(309)
Net loss	$ (29,546)					(29,546)
Ending balance (in shares) at Jun. 30, 2022	36,182,297		36,182,297
Ending balance at Jun. 30, 2022	$ 147,788		$ 3	$ 421,781	$ (1,259)	$ (272,737)

[1] The condensed balance sheet as of December 31, 2021 has been derived from the audited financial statements as of that date.